Hultström, Michael
Lipcsey, Miklos
Morrison, Dave R.
Nakanishi, Tomoko
Butler-Laporte, Guillaume
Chen, Yiheng
Yoshiji, Satoshi
Forgetta, Vincenzo
Farjoun, Yossi
Wallin, Ewa
Larsson, Ing-Marie
Larsson, Anders
Marton, Adriana
Titze, Jens Marc
Nihlén, Sandra
Richards, J. Brent
Frithiof, Robert
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dehydration is associated with production of organic osmolytes and predicts physical long-term symptoms after COVID-19: a multicenter cohort study
https://doi.org/10.1186/s13054-022-04203-w
Chest dual-energy CT to assess the effects of steroids on lung function in severe COVID-19 patients
https://doi.org/10.1186/s13054-022-04200-z
Documents that mention this clinical trial
Dehydration is associated with production of organic osmolytes and predicts physical long-term symptoms after COVID-19: a multicenter cohort study
https://doi.org/10.1186/s13054-022-04203-w
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (KAW 2020.0182)
Hjärt-Lungfonden (20210089, 20190639, 20190637)
Svenska Läkaresällskapet (SLS-938101)
Japan Society for the Promotion of Science for Young Scientists
Canadian Institutes of Health Research (CIHR: 365825)
Lady Davis Institute of the Jewish General Hospital
Canadian Foundation for Innovation
NIH Foundation
Cancer Research UK
Genome Québec
Public Health Agency of Canada
McGill University
Fonds de Recherche Québec Santé
Vetenskapsrådet (2014-02569, 2014-07606)
Swedish Kidney Foundation (F2020-0054)
Uppsala University
Article History
Received: 20 July 2022
Accepted: 14 October 2022
First Online: 21 October 2022
Declarations
:
: The National Ethical Review Agency approved the study Dnr 2017-043 (with amendments 2019-00169, 2020-01623, 2020-02719, 2020-05730, 2021-01469), as well as de-novo application Dnr 2022-00526-01 pertaining to the acute study, and Dnr 2020-02697 (with amendments 2020-03629, 2020-05758, 2021-02205, 2022-01115-02) pertaining to the follow-up study. The Declaration of Helsinki and its subsequent revisions were followed. Written informed consent was obtained from the patients when possible. Otherwise, informed consent was first asked from next to kin and later confirmed by patients if feasible. The study was registered à priori (clinicaltrials.gov: NCT04316884 and NCT04474249). The Biobanque Québécoise de la COVID-19 (BQC19) received ethical approval under the REB of the the Centre Hospitalier de l’Universite de Montréal (MP-02-2020-8929) and Jewish General Hospital (2020-2137).
: Not applicable.
: JBR served as an advisor to GlaxoSmithKline and Deerfield Capital, and is the founder and CEO of 5 Prime Sciences. VF and YF are employed by 5 Prime Sciences. YF consults for Fulcrum Genomics. The other authors declare that they have no conflicts of interest.